Clinical Trial Update: Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update indicates Dyne Therapeutics is evaluating Zeleciment Basivarsen (DYNE-101) for efficacy, safety, and tolerability in participants …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy Type

Drugs mentioned

• Zeleciment Basivarsen (basivarsen)

Snippet

Sponsor: Dyne Therapeutics | Conditions: Myotonic Dystrophy Type 1 (DM1), DM1 | Phase 3 | Status: RECRUITING